Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are effective and safe lipid-lowering treatments (LLT). The primary endpoint of the study was to assess the prevalence of patients eligible for treatment with PCSK9 inhibitors in a real-life clinical setting in Italy before and after t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fogacci, Federica, Giovannini, Marina, Grandi, Elisa, Imbalzano, Egidio, Degli Esposti, Daniela, Borghi, Claudio, Cicero, Arrigo F. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410302/
https://www.ncbi.nlm.nih.gov/pubmed/36012937
http://dx.doi.org/10.3390/jcm11164701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410302/
https://www.ncbi.nlm.nih.gov/pubmed/36012937
http://dx.doi.org/10.3390/jcm11164701

Ejemplares similares